



Innovative Medicines Initiative

IMI and IMI2: from science to patients

Richard Bergström
Director General, EFPIA

IMI – the success story


- * Proof of concept for new public private collaborations in pharmaceuticals – today the largest PPP in healthcare research
- * IMI connects the dots: science, research, health, regulatory and clinical practice
- * IMI works: tangible deliverables after less than 2 years – a pace that no other funding scheme allows

Our reality



- * Evolving business model
 - Shift from in house to external collaborations
- * R&D productivity challenges
 - Outputs vs cost
- * Regulatory and healthcare systems not ready for new sciences outputs
 - based on symptomatic approach to disease
- * Disconnect between pipeline focus and healthcare challenges
 - uptake of innovation is slow
- * Healthcare systems managing disease/ill-condition and not healthy living
 - the entire burden of disease does not drive health policy choices
- * PPPs and other collaborative schemes are mushrooming in other regions (US, Japan, China, ...)
 - competition and coordination

Is the current R&D model sustainable ?




Sources: Drug Discovery and Development: Understanding the R&D Process, www.innovation.org; CBO, *Research and Development in the Pharmaceutical Industry*, 2006

The Evolution of IMI: From bottlenecks in industry – to bottlenecks in Industry and Society



Make Drug R&D processes in Europe more efficient and effective
and enhance Europe's competitiveness in the Pharma sector



SRA – Strategic Research Agenda

IMI implements EU policies



Commission
Directorate-General for Health & Consumers

the Commission to
ent and the Council
threats from Antimicrobial

COM(2011)748




Personalised medicine conferences and workshops


2011 Conference
European Perspectives in Personalised Medicine
Square-Brussels Meeting Centre, Brussels, Belgium - 12-13 May 2011.



The virtuous cycle of R&D investments




From bottlenecks in industry to bottlenecks in society – fulfilling the promise of science




The Strategic Research Agenda for IMI2: A Three dimensional approach

- * The right prevention and treatment for the right patient at the right time
- * An ambitious agenda built on IMI success story: excellent science, excellent results, excellent collaborations
- * To deliver on the promises of science and make real impact



Healthcare Solutions: Effective delivery of the right prevention and treatment, to the right patients, at the right time

Common Standards for Data/Knowledge Sharing



Cross-industry / regulator /HTA / payer/
patient collaboration

The measures of success

